WallStSmart
KMDA

Kamada

NASDAQ: KMDA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$8.03
-1.60% today

Updated 2026-06-03

Market cap
$414.54M
P/E ratio
20.49
P/S ratio
2.28x
EPS (TTM)
$0.35
Dividend yield
3.49%
52W range
$6 – $9
Volume
0.1M

WallStSmart proprietary scores

55
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+
8.5
Quality
A
6.0
Profitability
B
6.0
Valuation
B
4/9
Piotroski F-Score
Moderate
2.6
Altman Z-Score
Grey zone
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$13.00
+61.99%
12-Month target
$7.06
-12.02%
Intrinsic (DCF)
$7.80
Margin of safety
-7.18%
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Debt/equity 0.04x — low leverage
Risks
- Negative free cash flow $-1.26M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$129.34M$142.52M$160.95M$180.46M$181.68M
Net income$-2.32M$8.28M$14.46M$20.20M$4.13M
EPS$0.35
Free cash flow$24.80M$-1.53M$36.85M$16.93M$-1.26M
Profit margin-1.79%5.81%8.99%11.19%11.20%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
KMDA$414.54M555.36.06.08.5-7.18%Buy
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Kamada trades at $8.03. representing a P/E of 20.49x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.56, it sits in the grey zone. TTM revenue stands at $181.68M. with profit margins at 11.20%. Our DCF model estimates intrinsic value at $7.80.

Frequently asked questions

What is Kamada's stock price?

Kamada (KMDA) trades at $8.03, on a P/E of 20.5x and a P/S of 2.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Kamada overvalued?

Kamada carries a Smart Value Score of 55/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $7.80 against the $8.03 price, so on cash flow terms the market is paying a premium for Kamada's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.

What is the price target of Kamada (KMDA)?

The 12-month analyst consensus target is $13.00, about 62.0% above the current $8.03. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

What is the future stock price of KMDA by 2030?

Our research-backed model puts the 2030 base case at $11.18, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.

What is the intrinsic value of Kamada (KMDA)?

Our DCF model estimates intrinsic value at $7.80, a -7.2% margin of safety versus today's $8.03. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.

What is Kamada's revenue?

Kamada's trailing twelve-month revenue is $181.68M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Altman Z-Score?

Kamada's Altman Z-Score is 2.56, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio2.28x
ROE7.85%
Beta0.15
50D MA$8.15
200D MA$7.66
Shares out0.06B
Float0.01B
Short ratio
Avg volume0.1M

Performance

1 week+0.00%
1 month-7.91%
3 months-15.06%
YTD+4.67%
1 year
3 years
5 years